Jazz Pharmaceuticals (JAZZ) Gets Price Target Boost Following Positive Xywav Phase 4 Data

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) ranks among the stocks with low beta that can beat market volatility. On September 23, Morgan Stanley reaffirmed its Overweight rating on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and raised its price target from $163 to $167. The adjustment came after Jazz Pharmaceuticals plc (NASDAQ:JAZZ) revealed findings from the Xywav Phase 4 DUET open-label research at World Sleep Singapore through many poster presentations.

The study’s findings indicate that oxybates, the family of medications that contains Xywav, are distinct from other therapies and will likely continue being an essential treatment for hypersomnias, according to Morgan Stanley. In light of these findings, the firm has raised its estimated market share for Jazz’s oxybate products in its financial models.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a biopharmaceutical company that develops treatments for serious illnesses. Its key products include Xywav, Xyrem, Epidiolex, Rylaze, Zepzelca, Defitelio, and Vyxeos.

While we acknowledge the potential of JAZZ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.